CPG for Community-acquired Pneumonia (CAP) in Immunocompetent Adults 2016
Internationally, community-acquired pneumonia (CAP) remains the leading cause of death from an infectious disease. It is the sixth leading cause of death overall and is a major cause of morbidity and mortality. Since the last publication of Philippine Clinical Practice Guidelines on the Diagnosis, Empiric Management, and Prevention of Community-acquired Pneumonia (CAP) in Immunocompetent Adults in 2010, several changes had emerged:
Multiple international societies had published and revised their guidelines of the management of patients with CAP.
New organisms had emerged and development of resistance had increased over time among respiratory pathogens.
The influx and efflux of antimicrobial agents used in the treatment had likewise posed a threat to the rapid rise of antimicrobial resistance. The use, misuse, abuse and overuse had also shaken the market of antimicrobial agents.
It is for these reasons that a long overdue update on the management of CAP is needed. There is a need to standardize care by providing management strategies based on best available evidences. The evidences may be the same; however, regional differences, causative agents, antibiotic resistance rates, drug licensing, healthcare structure and available resources may vary. Recommendations made by one national organization may therefore not be applicable to other countries
DOWNLOAD the Clinical Practice Guidelines for Community-acquired Pneumonia (CAP) in Immunocompetent Adults 2016 here.
CPG CAP 2016